Results 261 to 270 of about 1,832,641 (315)
Some of the next articles are maybe not open access.

Analysis of reimbursement (R) for next generation sequencing (NGS) on patients' tumors in the context of a personalized medicine program.

Journal of Clinical Oncology, 2017
6506 Background: R policies for NGS testing vary widely among private and public insurers. While drug costs are the greatest challenge in personalized or precision medicine, cost and R are substantial barriers to genomic profiling with NGS. We examined variation in coverage and R for a cohort of cancer patients (pts) treated at a tertiary oncology ...
Thomas D. Brown   +19 more
openaire   +1 more source

Commentary on R&D Trends Away from General Medicine/Cardiovascular Drugs: Can the FDA Help Reverse the Trend?

Clinical Pharmacology & Therapeutics, 2017
In the latter part of the 20th century, drug development in cardiovascular diseases (CVDs) was a paragon of “modern” therapeutics, bringing about a substantial number of effective, well‐tolerated agents targeting some of the most prevalent diseases of the Western world.
openaire   +2 more sources

General Medicinal Properties and Biocompatibility of Hemidesmus indicus R. Br. Aqueous Plant Extract

2023
Hewa Dikkumburage Tharindu Madhuranga   +6 more
openaire   +1 more source

Radiotheranostics in oncology: Making precision medicine possible

Ca-A Cancer Journal for Clinicians, 2023
Eric O Aboagye   +2 more
exaly  

Clinical management of metastatic colorectal cancer in the era of precision medicine

Ca-A Cancer Journal for Clinicians, 2022
Fortunato Ciardiello   +2 more
exaly  

Corrigendum to “The impact of computer use on myopia development in childhood: The Generation R study” [Preventive Medicine, Volume 132, 2020, 105988]

Preventive Medicine
Clair A. Enthoven   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy